Results 121 to 130 of about 51,116 (225)

The effect of angiotensin receptor neprilysin inhibitor, sacubitril/valsartan, on central nervous system amyloid-β concentrations and clearance in the cynomolgus monkey [PDF]

, 2017
Bateman, Randy J, et al,
core   +2 more sources

Sacubitril/Valsartan Attenuates Inflammation and Fibrosis Associated With Decreased Integrin α8 and Inhibits Hepatocarcinogenesis in a Rat Model of Metabolic Dysfunction‐Associated Steatohepatitis

Hepatology Research, Volume 56, Issue 4, Page 420-435, April 2026.
Sacubitril/Valsartan (Sac/Val) alleviates fibrosis and inflammation in metabolic dysfunction‐associated steatohepatitis (MASH). Its anti‐fibrotic effect is linked to the suppression of Integrin alpha 8 (Itga8), a protein crucial for hepatic stellate cell (HSC) activation and collagen production.
Hayato Kawamura, Aya Naiki‐Ito, Xiaochen Kuang, Akihiro Murakami, Masayuki Komura, Takanori Suzuki, Hiroyuki Kato, Yuko Nagayasu, Kentaro Matsuura, Kei Fujiwara, Hiromi Kataoka, Satoru Takahashi   +11 more
wiley   +1 more source

Effect of Sacubitril/Valsartan vs Standard Medical Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX Randomized Clinical Trial.

Journal of the American Medical Association (JAMA), 2021
B. Pieske, R. Wachter, Sanjiv J. Shah, A. Baldridge, Peter Szeczoedy, G. Ibram, V. Shi, Ziqiang Zhao, M. Cowie   +8 more
semanticscholar   +1 more source

Targeting Arterial Dysfunction in Cardiovascular Disease Using Stem Cell‐Based Therapies

The FASEB Journal, Volume 40, Issue 6, 31 March 2026.
Graphical presentation of stem cell‐based therapies for arterial dysfunction, endothelial repair and regeneration strategies. SMC, smooth muscle cell. ABSTRACT Arterial regeneration represents a critical frontier in cardiovascular medicine, as progressive endothelial dysfunction, maladaptive vascular smooth muscle cell (SMC) plasticity, and chronic ...
Yun‐Yu Ma, Shu‐Yao Zhu, Yi Song
wiley   +1 more source

Angiotensin II receptor antagonists for the treatment of heart failure: what is their place after ELITE-II and Val-HeFT? [PDF]

, 2001
McMurray, John J.V.
core   +1 more source

Correction to ‘Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting’

ESC Heart Failure, Volume 12, Issue 2, Page 1525-1525, April 2025.
wiley   +1 more source

Valsartan [PDF]

, 2020
openaire   +1 more source

Hypertension and its complications in a young man with autoimmune disease [PDF]

, 2017
Basile, Jan N., Batlle, Daniel C., Dhaun, Neeraj, Dominiczak, Anna F., Elijovich, Fernando, Jennings, Garry L.R., Laffer, Cheryl L., Miller-Hodges, Eve, Oliveras, Anna, Oparil, Suzanne   +9 more
core   +1 more source

You evaluation of the PARACHUTE-HF trial: role of sacubitril/valsartan compared to enalapril on outcomes in patients with heart failure from Chagas' disease. [PDF]

Heart Fail Rev
Abramov D, Minhas AMK, Alexy T, Guimaraes PO, Lainscak M, Myhre PL.   +5 more
europepmc   +1 more source

TangShenWeiNing formula alleviates diabetic kidney disease by inhibiting ferroptosis via AMPK pathway in renal tubular epithelial cells. [PDF]

Front Endocrinol (Lausanne)
Jiang Y, Chang J, Guo Y, Liu Z, Feng X.
europepmc   +1 more source